Pharma's Experiment With India's Borrow And Treat Model
This article was originally published in Scrip
Executive Summary
When a 52-year-old Indian cart-seller of plastic toys was hospitalized because of a cardiac condition the first time, his family decided against going through with the treatment. They simply could not afford the costs involved.
You may also be interested in...
Will 'Financial Toxicity’ Weigh Down 1L NSCLC Win For Tagrisso In India?
The price factor could potentially shrink the patient pool in first line non-small cell lung cancer for Tagrisso in largely out-of-pocket markets like India, though AstraZeneca has put in place a patient assistance program in this market for those can’t afford the medicine.
Will Keytruda Price Differential Really Count In India?
Merck has launched Keytruda at an “India-specific” price but some experts say that the immuno-oncology therapy will likely still be beyond the reach of a majority of patients. Merck though also expects to offer a patient access program for those who can’t afford the therapy.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.